ストックスクリーナーアプリを入手
2.41
133.98%
1.38
アフターアワーズ：
2.48
0.07
+2.90%
前日終値:
$1.03
開ける：
$2.3
24時間の取引高:
258.91M
Relative Volume:
61.81
時価総額：
$41.52M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+121.10%
1か月 パフォーマンス:
-38.21%
6か月 パフォーマンス:
-30.14%
1年 パフォーマンス:
-41.08%
1日の値動き範囲:
$2.21
$3.2099
1週間の範囲:
$0.95
$3.2099
52週間の値動き範囲:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
MURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.41 | 41.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.49 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.38 | 36.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.93 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.84 | 25.73B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-04-04 | 開始されました | Morgan Stanley | Overweight |
Mural Oncology Plc (MURA) 最新ニュース
Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On? - Benzinga
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
Raymond James cuts Mural Oncology target to $4, retains outlook By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Mural Oncology Shares Jump as it Seeks Strategic Alternatives; Co. Discontinues Nemvaleukin Alfa Development - MarketScreener
Mural Oncology halts nemvaleukin trials, seeks strategic options - Investing.com
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Mural Oncology Ends Nemvaleukin Program, Begins Strategic Review - Nasdaq
Mural Oncology Announces Plans To Explore Strategic Alternatives - MarketScreener
Mural Oncology Skyrockets on News of Strategic Shake-Up - Wall Street Pit
Mural Oncology to Explore Strategic Alternatives, Cut Workforce by 90%; Shares Jump Pre-Bell - MarketScreener
Why MURA Stock Goes Parabolic Today - Own Snap
Mural Oncology halts nemvaleukin trials, seeks strategic options By Investing.com - Investing.com India
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Failed Cancer Trial Forces Mural Oncology to Halt Development and Cut 90% of Workforce - Stock Titan
Research Analysts’ Recent Ratings Updates for Mural Oncology (MURA) - Defense World
Raymond James Financial Inc. Makes New Investment in Mural Oncology plc (NASDAQ:MURA) - Defense World
IL-2 ADding contenders in eczema strategy - BioWorld MedTech
Spin-Off Research Slashes Mural Oncology Valuation - Forbes
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer - Curetoday
40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC - Defense World
HC Wainwright Comments on Mural Oncology Q1 Earnings - Defense World
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects - Seeking Alpha
HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00 - Defense World
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
Mural Oncology stock target cut to $6 at H.C. Wainwright By Investing.com - Investing.com UK
Mural Oncology downgraded to Hold from Buy at JonesResearch - TipRanks
Raymond James downgrades Mural Oncology after ovarian cancer failure - TipRanks
Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform - Defense World
Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading - Defense World
Mural Oncology (NASDAQ:MURA) Downgraded to “Equal Weight” Rating by Morgan Stanley - Defense World
Raymond James cuts Mural Oncology stock rating, slashes target to $6 - Investing.com UK
Morgan Stanley cuts Mural Oncology stock rating to Equal-weight By Investing.com - Investing.com UK
Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% - Clinical Trials Arena
Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks
Mural Oncology halts ovarian cancer drug development By Investing.com - Investing.com South Africa
Mural Oncology sinks on nemvaleukin miss in ovarian cancer - BioWorld MedTech
Mural Oncology halts ovarian cancer trial By Investing.com - Investing.com South Africa
US Stocks Mixed; Core & Main Posts Downbeat Earnings - Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Jones Trading cuts Mural Oncology stock rating to hold By Investing.com - Investing.com UK
Mural Oncology halts ovarian cancer trial - Investing.com India
Mural Oncology halts ovarian cancer drug development - Investing.com India
Mural Oncology to Stop Development of Nemvaleukin for Ovarian Cancer; Shares Sink Pre-Bell - MarketScreener
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - The Manila Times
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Clinical Trial Setback: Mural's Cancer Drug Falls Short in Phase 3 Ovarian Cancer Study - Stock Titan
Mural Oncology Plc (MURA) 財務データ
Mural Oncology Plc (MURA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.98%
5.78%
大文字化:
|
ボリューム (24 時間):